Celltrion and Kaigene sign $580m licence deal for KG013

​

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

The post Celltrion and Kaigene sign $580m licence deal for KG013 appeared first on Hospital Management.

 

Back to the Featured Stories
Celltrion and Kaigene sign $580m licence deal for KG013

Featured Stories

Medtronic reports real-world findings for cardiac ablation systems
Granata Bio concludes screening in Phase III GRACE trial for IVF
Edwards secures FDA approval for tricuspid valve repair system
Lynch’s rhPDGF-BB IND secures FDA clearance for Phase II trial
MSD’s Keytruda and Padcev combination receives EC approval

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us